Accumulating evidence suggests that the Nrf2/Keap1 pathway is implicated in diabetic oxidative damage to several peripheral tissues, and the pharmacological activation of Nrf2 is expected to be a promising therapeutic approach for T2DM [119,129,130]. This evidence concerns the gene NFE2L2 and type 2 diabetes mellitus.